• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Treatment with RYBREVANT and Lazertinib Showed Survival in Advanced NSCLC

    PR NEWSWIRE

    Janssen Submits MAA to the EMA Seeking Approval of Erdafitinib

    GLOBENEWSWIRE

    Janssen Submits sNDA to the USFDA Seeking Full Approval of BALVERSA for MUC

    PR NEWSWIRE

    Janssen submits sBLA to FDA for NSCLC combination therapy

    PHARMACEUTICAL TECHNOLOGY

    Janssen Submits sBLA to FDA Seeking Approval of RYBREVANT for NSCLC

    PR NEWSWIRE

    J&J`s Janssen to close part of its vaccine division

    REUTERS

    EC grants CMA to Janssen`s Talvey for multiple myeloma

    PRESS RELEASE

    Alkermes` $194M payment from Janssen gets approval from court

    ENDPTS

    EC Approves Reduced Dosing Frequency for Janssen™s Bispecific Antibody TECVAYLI

    GLOBENEWSWIRE

    FDA approves J&J`s PARP combo drug Akeega for prostate cancer

    FDA

    Janssen Biotech`s Biologic Talvey (talquetamab) Receives Approval in the U.S.

    FDA

    Erleada Approved as the Only Androgen Receptor Inhibitor in Canada

    NEWSWIRE

    Janssen`s Biologic Talvey (talquetamab) Receives Approval in the U.S.

    FDA

    Janssen Biotech`s Biologic Tecvayli (teclistamab) Receives Approval in the U.S.

    FDA

    Janssen`s infectious disease partners left in the lurch

    FIERCE BIOTECH

    Janssen Receives Positive CHMP Opinions for Antibodies TALVEY and TECVAYLI

    GLOBENEWSWIRE

    Janssen`s merged infectious disease and vax pipeline is halved

    FIERCE BIOTECH

    LianBio Partner NANOBIOTIX Enters into Agreement with Janssen for NBTXR3

    GLOBENEWSWIRE

    Treatment with RYBREVANT Plus Chemotherapy Resulted in Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with Newly Diagnosed EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer

    PR NEWSWIRE

    J&J to move oral IL-23 drug into late-stage studies for plaque psoriasis

    PR NEWSWIRE

    FMF World Congress 2023: Janssen shares new data in HDFN

    EUROPEAN PHARMACEUTICAL REVIEW

    J&J touts PhII data in rare blood disorder as it plots a pivotal study

    ENDPTS

    New Phase 2 Data Demonstrate Benefit of Nipocalimab for Pregnant Individuals

    PR NEWSWIRE

    Janssen Submits MAA to EMA Seeking Approval of STCT of Macitentan & Tadalafil

    GLOBENEWSWIRE

    New PII Data Demonstrate Benefit of Nipocalimab for Pregnant Individuals

    GLOBENEWSWIRE

    Physicians rate Janssen, Merck & Novo Nordisk best for customer experience in US

    ENDPTS

    MRCT Center and Medable Launch First, Comprehensive IRB/EC Review

    BUSINESSWIRE

    Janssen`s Rekambys (Rilpivirine) Receives Approval in Europe

    EMA

    Janssen Submits sBLA to U.S. FDA Seeking Approval of CARVYKTI

    PRESS RELEASE

    Alkermes Announces Final Award in Janssen Arbitration

    PR NEWSWIRE

    Janssen Announces Erdafitinib Improved Overall Survival Versus Chemotherapy

    GLOBENEWSWIRE

    CARVYKTI Reduces Risk of Death by 74% in Earlier-Line Multiple Myeloma

    GLOBENEWSWIRE

    Janssen Presents Longer-Term Data for TECVAYLI® (teclistamab-cqyv) Showing a Duration of Response of 22 Months in Patients with Relapsed or Refractory Multiple Myeloma

    GLOBENEWSWIRE

    Data from the CHRYSALIS Study Show Median Progression-Free Survival Not Reached

    PR NEWSWIRE

    Data from the CHRYSALIS Study Show Progression-Free Survival Not Reached

    GLOBENEWSWIRE

    Janssen Presents First Results from Dual Bispecific Combination Study

    GLOBENEWSWIRE

    Janssen Presents Longer-Term Talquetamab Follow-Up Data Showing Overall Response Rates of More Than 70 Percent in Heavily Pretreated Patients with Multiple Myeloma

    GLOBENEWSWIRE

    Janssen Tremfya excels as psoriasis treatment, outshining IL-17s

    INDIAN PHARMA POST

    Janssen Submits NDA to FDA Seeking Approval of Invg Single Tab ComboTherapy

    PR NEWSWIRE

    Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications

    PRESS RELEASE

    Janssen reports decline in 2022 net prices as out-of-pocket costs grow

    ENPTS

    Janssen Seeks European Commission Approval of a New Indication for CARVYKTI

    GLOBENEWSWIRE

    Janssen to Highlight Advances and Commitment to Transform Cancer Care at ASCO

    PRESS RELEASE

    Protagonist Reports Positive Results from Ph1 &Preclinical Studies Oral JNJ-2113

    PR NEWSWIRE

    Janssen’s Tremyfa scores success in Phase III ulcerative colitis trial

    CLINICAL TRIALS ARENA

    First Phase 3 TREMFYA® Data in Inflammatory Bowel Disease +Ve Results

    PR NEWSWIRE

    J&J refuels CAR-T ambitions with $245M Cellular Biomedicine deal

    FIERCE BIOTECH

    Janssen Reports First Results from Phase 2 SunRISe-1 Study of TAR-200

    PR NEWSWIRE

    Janssen gets priority review for prostate cancer; ImmunoGen reports Q1 sales

    ENDPTS

    China Approves Sales of Janssen’s Antidepressant

    YICAIGLOBAL

    Janssen to Highlight Innovation in Retinal Pipeline at ARVO

    PR NEWSWIRE

    NICE gives green light to ibrutinib plus venetoclax for lymphocytic leukaemia

    PHARMIWEB

    Genmab Announces Initial Resolution of Its 2nd Arbitration Agreementwith Janssen

    GLOBENEWSWIRE

    Janssen taps into Pipeline Therapeutics’ neuroscience asset for $50M upfront

    ENDPTS

    Erleada, First Next-Generation Androgen Receptor Inhibitor Available in U.S.

    PR NEWSWIRE

    Janssen Provides Portfolio Update

    PR NEWSWIRE

    New RYBREVANT Data Showed Long-Term Clinical Response and Safety in Patients

    PR NEWSWIRE

    New Data from the Phase 3b ESCAPE-TRD Study Show that Participants Receiving SPRAVATO Achieved Higher Response and Remission Rates, Increasing Over Time, Compared to those Receiving Quetiapine Extended-Release

    GLOBENEWSWIRE

    Janssen announces dengue antiviral demonstrates efficacy in pre-clinical data

    INDIAN PHARMA POST

    TREMFYA Real-World Data Analyses Show Greater Treatment Persistence Than IL-17s in Both Bio-naïve and Bio-experienced Patients Living With Moderate to Severe Plaque Psoriasis

    PR NEWSWIRE

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.